How long does it take to take the targeted drug Alpelisib?

Alpelisib (Alpelisib)-Piqray is a selective PI3Kα inhibitor, mainly used to treat patients with hormone receptor-positive, HER2-negative advanced breast cancer who carry PIK3CA mutations. It blocks the growth and metabolism of cancer cells by inhibiting the PI3K/AKT signaling pathway, thereby delaying disease progression. As for the length of medication, there is no fixed period, but is dynamically adjusted according to the patient's tolerance, efficacy and changes in the condition.

Apelix is a long-term oral maintenance treatment drug. Most patients will continue taking the drug until disease progression or intolerable side effects occur. Common clinical use cycles can last for months or even years. Its treatment concept is not to "clear cancer cells in the short term", but to keep cancer cells in a "growth-restricted" state by long-term inhibition of mutation signaling pathways, thereby maintaining the stability of the disease. Because of this, doctors usually advise patients to take it strictly on time and not to stop taking it or reduce the dosage on their own.

During long-term medication, Apelvis may cause a series of metabolic-related adverse reactions, such as hyperglycemia, rash, diarrhea, or weight loss. Hyperglycemia is one of the more typical side effects, so it is recommended that patients monitor blood sugar levels regularly during treatment and manage diet and hypoglycemic drugs under the guidance of a doctor. If the side effects are mild, the doctor will continue to maintain the treatment by adjusting the dose (such as reducing from 300mg to 250mg or 200mg); if severe toxicity occurs, it may be necessary to temporarily stop the medication or change to another regimen.

Determinants of medication time also include the patient’s tumor genetic status and tumor burden. If PIK3CA mutation driver is obvious and drug control is good, patients may obtain a longer progression-free survival and thus prolong the medication time. On the contrary, if the patient is combined with other mutations or develops secondary resistance, the maintenance time of the therapeutic effect may be relatively shortened.

Reference materials:https://www.piqray.com/